Clinical trials: Chronic Disease of Cardiovascular System
Congestive Heart Failure Chronic, Low Ejection Fraction
Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)
The goal of this trial is to determine if the addition of the Heart Logic diagnostic alerts to standard of care therapies will lessen hospitalizations and improve quality of life in patients with heart failure.
- Trial name
- Heartlogic ISR (NCT07412626)
- Testing
- Heartlogic Diagnostic Tool Threshold Change, Heartlogic Diagnostic Tool Unchanged Threshold
- Where
- 2 sites in United States
- Volunteers
- 135 people
- Sponsor
- Robert Pickett
Pulmonary Disease, Chronic Obstructive
Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or other LABAs available for…
- Trial name
- NCT03405363
- Where
- Denmark
- Volunteers
- 65,406 people
- Sponsor
- Boehringer Ingelheim
Hematologic Malignancies, Waldenstroms Macroglobulinaemia
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's…
- Conditions
- Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
- Trial name
- NCT04728893
- Testing
- Nemtabrutinib
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 490 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure
Heart Failure Patients Registry
This study is a multicenter non-interventional observational prospective registry. This non-interventional study (NIS) does not imply any intervention into a routine clinical practice, including choice of treatment modality or…
- Trial name
- Priority-HF (NCT04709263)
- Where
- 65 sites in Russia
- Volunteers
- 19,990 people
- Sponsor
- AstraZeneca
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW III Asia Registry Orsiro Stent System
Cliflical evaluation of th' Orsiro LESS 10 diabetic subjects requiring coronary revasculariza t ion with Drug Eluting Stefl ts (DES) .880 subjects will be enrolled in this registry.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01941290
- Where
- 19 sites in China, India and 3 more
- Volunteers
- 387 people
- Sponsor
- BIOTRONIK Asia Pacific Pte Ltd
Chronic Kidney Disease (CKD)
A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction (IR)
The primary objective of this clinical study is to evaluate the preliminary safety and effectiveness of using the FLEX-1 device for the creation of an arteriovenous fistula (AVF) including coiling of the brachial vein during the…
- Trial name
- NCT02119832
- Testing
- Endovasccular AVF (EndoAVF)
- Where
- Paraguay
- Volunteers
- 17 people
- Sponsor
- C. R. Bard
Peripheral Arterial Disease
Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease
The goal of this clinical trial is to study the safety and tolerability of Etrinabdione in adult patients with peripheral arterial disease. It will also learn about the preliminary efficacy of Etrinabdione.
- Trial name
- CLAUDIA (NCT06774040)
- Testing
- Etribnabdione 25 mg BID, Etribnabdione 50 mg BID
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- VivaCell Biotechnology España
Heart Failure, Congestive
Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5
The purpose of this study is to determine whether treatment with the OPTIMIZER System is safe and effective in patients with moderate to severe heart failure symptoms.
- Trial name
- NCT00112125
- Testing
- OPTIMIZER System
- Where
- United States
- Volunteers
- 428 people
- Sponsor
- Impulse Dynamics
Heart Failure
Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease
The purpose of this study is to determine the effects of CLP on serum potassium and signs and symptoms of fluid overload in heart failure patients with chronic kidney disease.
- Trial name
- NCT01265524
- Testing
- CLP
- Where
- 3 sites in Armenia, Georgia and 1 more
- Volunteers
- 113 people
- Sponsor
- Sorbent Therapeutics
Sialorrhea
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
- Trial name
- OPTIMYST (NCT02610868)
- Testing
- MYOBLOC
- Where
- 35 sites in United States, Belarus and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Type 2 Diabetes, Hypertension
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
- Conditions
- Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
- Trial name
- iCaReMe (NCT03549754)
- Where
- 76 sites in Brazil, Chile and 18 more
- Volunteers
- 35,000 people
- Sponsor
- AstraZeneca
Chronic Heart Failure With Reduced Ejection Fraction
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
The purpose of this randomized, actively controlled, double-blind study with prospective data collection was to assess differences between sacubitril/valsartan versus enalapril in increasing exercise capacity and non-sedentary…
- Trial name
- OUTSTEP-HF (NCT02900378)
- Testing
- LCZ696 (Sacubitril/Valsartan), Enalapril
- Where
- 119 sites in Belgium, Bulgaria and 17 more
- Volunteers
- 621 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Subdural Hematoma, Subdural Hematoma, Chronic
Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH)
The aim of the study is to proof the effectiveness of Histoacryl® on preventing recurrence or progression of subdural hematoma after embolization of the middle meningeal artery.
- Trial name
- HARMONY (NCT07258069)
- Testing
- Histoacryl®
- Where
- 6 sites in Japan
- Volunteers
- 178 people
- Sponsor
- Aesculap AG
Heart Failure
Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure
Evaluate the efficacy and safety of Jia Shen Tablets in patients with Chronic Heart Failure.
- Trial name
- NCT06669169
- Testing
- Low dose Jia Shen Tablet, High dose Jia Shen Tablet
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Critical Limb Ischemia, Ischemia
HemaTrate™ in the Treatment of Critical Limb Ischemia
The primary objective of this study is to evaluate the performance of the HemaTrate™ Blood Filtration system in the treatment of critical limb ischemia.
- Trial name
- NCT03809494
- Testing
- HemaTrate™ Blood Filtration system, Saline
- Where
- 3 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- Cook Research Incorporated
Diabetic Foot Ulcer
Topical Erythropoietin Hydrogel Formulation for Diabetic Foot Ulcers
Remedor has developed a patented technology (RMD-G1), which comprises erythropoietin (EPO) as the active pharmaceutical ingredient (API) in a carbopol-based hydrogel with an FN matrix.
- Trial name
- Remede d'Or (NCT02361931)
- Testing
- A hydrogel containing erythropoietin, Hydrogel (as a part of SOC)
- Where
- 5 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Remedor Biomed Ltd
Angina Pectoris
Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina
The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.
- Trial name
- T89 phase 2 (NCT00797953)
- Testing
- T89
- Where
- 15 sites in United States
- Volunteers
- 124 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Chronic Spontaneous Urticaria, Angioedema
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
This study will assess the impact of omalizumab on the quality of life improvement when added to the standard therapy in refractory patients suffering from chronic spontaneous urticaria and angioedema.
- Trial name
- X-ACT (NCT01723072)
- Testing
- Omalizumab
- Where
- 25 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM)
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 5.
- Conditions
- Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM), Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03174522
- Testing
- REX-001
- Where
- 15 sites in Czechia, Hungary and 4 more
- Volunteers
- 49 people
- Sponsor
- Ixaka Ltd